Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Healthscope Ltd Says ‘No Deal’ To AustralianSuper & Brookfield

Healthscope Ltd (ASX: HSO), the private hospital operator which finds itself the target of two takeover offers from a consortium led by AustralianSuper and another from Brookfield, this morning provided an update on the potential deals.

Healthscope is one of Australia’s largest private hospital operators. It recently received takeover offers from AustralianSuper and BGH Capital for $2.36 per share, and another $2.50 per share offer from Brookfield Asset Management.

In an announcement today, Healthscope said it will not allow either of the parties to access the private deal room and undertake due diligence on the business. Healthscope said both offers undervalue the company.

“The Directors have carefully considered each proposal and concluded that neither proposal adequately reflects the long term value of Healthscope, nor its underlying assets nor future potential,” Healthscope Chairman Paula Dwyer said. “In the past twelve months, management has (sic) being laying the foundations for a significant improvement in business performance.”

Healthscope said the offers undervalue it because of expected improvements in the company’s operating performance, potential returns from projects and the value of the underlying property portfolio.

Healthscope Review

Healthscope said it reviewed both offers but will now conduct its own strategic review on its hospital property portfolio to, “explore the merits of a sale and leaseback transaction with a view to unlocking value for Healthscope shareholders in the near term.”

“Healthscope has an attractive and unique portfolio of property assets,” Dwyer noted. “A sale and leaseback transaction has the potential to reduce the quantum of property held on Healthscope’s balance sheet, free up capital and release significant value to shareholders.”

Ms Dwyer concluded by saying the industry’s long-term fundamentals and the prospects for Healthscope are positive.

Did The Last Takeover Work?

Healthscope was formed in 1984 and first listed on the stock exchange in 1994. In 2010 it was acquired by private equity owners and relisted in 2014 at $2.10 per share. Since then, the shares have risen modestly to their current price of $2.46.

Do you like investing but want to learn more? It’s free to join The Rask Group’s Investor Club Newsletter. It’s a regular (usually weekly) news and educational update on financial markets, investing and unique strategies. Join today and get ready to laugh and learn.

Click here to join The Rask Group’s Investor Club Newsletter Today

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content